Life Science Connect

Considering many Life Science Leader readers daydream of starting and leading their own biopharmaceutical company someday, we thought it would be informative to host an executive virtual roundtable with three biopharmaceutical company CEOs who have done just that.

Diversity & inclusion is — and has been — an important issue for the biopharmaceutical industry. As such, we thought it would be worthwhile to gain some perspective.

Fundraising used to always be done in person. But then COVID hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have actually become quite proficient at the process and the platforms. Three biopharma execs share some best practices of the virtual pitch.

According to Outsourced Pharma Chief Editor, Louis Garguilo, “politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while also discussing the current IP debate in pharma and the origins of the coronavirus.

We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they've done in the past.

We sat down with three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies' manufacturing and supply chains amidst a pandemic.

Three biopharmaceutical industry VPs of HR departments discuss the challenges of continued operations amidst COVID-19 initiated lockdowns, along with some of the best practices implemented.

Erin Harris, chief editor of cellandgene.com explains what makes cell and gene therapy manufacturing more complex what some of the current hurdles and bottlenecks are that companies in this sector of life sciences face.

Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, a clinical-stage oncology company; and Dara Lockert, founder and executive director of Spannerwerks, a life science industry consultancy, share best practices and lessons learned during the drive to get a biopharmaceutical startup to the clinic as quickly as possible.

Four biopharmaceutical industry CEOs and company cofounders converse on what their organizations are doing to spur the development of diagnostic tests, therapeutics, and vaccines in order to turn the tide on the COVID-19 pandemic.

Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic.

Three CEOs of publicly traded biopharmaceutical companies discuss how they are leading their organizations, while also managing the expectations of Wall St. during the COVID-19 pandemic.

Five biopharmaceutical industry CEOs discuss challenges their companies have faced, along with best practices implemented in managing through the COVID-19 chaos.

Starting in April 2021, each week we will be releasing the audio portion of various episodes of our popular Executive Virtual Roundtables (EVRs). In them, we cover topics such as leadership and drug development during COVID, how to accelerate a biopharma path to the clinic, virtual pitching and fundraising, and diversity and inclusion in pharma. You can watch all of our Executive Virtual Roundtable videos here.

BioProcess Online Chief Editor, Matt Pillar, discusses the current vaccine market, some advancements that have been made, and if its growth is sustainable. 

Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways. Our guest, ClinicalLeader.com Chief Editor, Ed Miseta, weighs in on this timely topic.

Life Science Leader Chief Editor Rob Wright has attended numerous JPM conferences, so he gives his feedback on how this year's virtual show compared to previous years.

Erin Harris, Chief Editor of cellandgene.com, reviews some of the hot cell and gene therapy topics for 2020 and what to watch for in 2021. She also discusses the upcoming Cell & Gene Live! event and the miniseries she did for the Business of Biotech podcast. 

2020 seems to be the year of the evolution of the atypical, newfangled CDMO. Outsourced Pharma Chief Editor Louis Garguilo talks about this trend and what makes these new models all the rage.

Today's guest, Matt Pillar, not only hosts two of his own podcasts, but is our Chief Editor for BioProcess Online. Matt gives a peek into what trends he wrote about for the Life Science Leader outlook issue, and he talks about what's next for his Business of Biotech podcast.

It was only a little more than a year ago when the phrase “throw in the towel” was being used in reference to the biosimilars industry. Now, some say we're in the “Golden Age” of biosimilars. Biosimilar Development Chief Editor, Anna Rose Welch, tries to explain to Dan why the big flip. 

Our guest, Outsourced Pharma Chief Editor Louis Garguilo, talks about the response from readers — and PhRMA — to his editorial, “Is PhRMA's White House Rebuttal Acceptable?”

Ever wonder how a pharma executive gets to be on the cover of Life Science Leader? For Tim Wright, CEO of MiMedx, it was a chance encounter at a leadership conference a few years ago. 

Outsourced Pharma Chief Editor Louis Garguilo elaborates on his recent editorial regarding the immense opportunity that Puerto Rico offers —and has offered for years — pharma manufacturers looking to bring back operations to the states.

Anna Rose Welch talks about a new whitepaper that explains why now is the best time for a U.S. biosimilars shared savings model.

Virtual conferences are here to stay ... for a while at least. Life Science Leader Chief Editor, Rob Wright, gives some of his pros and cons regarding these events based on his first-hand experiences these past few months.

Cell & Gene Chief Editor Erin Harris talks about a new study that predicts a dramatic rise in jobs for the cell and gene sector in Philadelphia and what's driving that change.

Our biosimilars expert, Anna Rose Welch, talks about a new peer-reviewed paper that strongly suggests we “re-think biosimilar development following today's regulatory science.” Check out her article “Show Me The Data: New Publication Moves Long-Held Regulatory Debate Forward” on BiosimilarDevelopment.com for more info on this topic.

Life Science Leader Chief Editor Rob Wright talks about why he chose AC Immune for an upcoming feature article and the evolution of the new video roundtables with top pharma execs. 

Ed Miseta of Clinical Leader talks about how the upcoming DIA conference is going to be different -- and the same -- and he gives details on the virtual CRO Leadership Awards.

One provocative article about reducing our reliance on foreign sources for drug development leads to some strange feedback, which leads to some additional intriguing articles.

Our guest Rob Wright talks about his conversations with a biotech startup that allowed him to review their pitch deck in preparation for some potential investor meetings.

Anna Rose Welch, Chief Editor of Biosimilar Development, discusses her foray into making videos for LinkedIn (along with her cat) and the state of the biosimilars industry, including some upcoming conferences.

Rob Wright, Chief Editor of Life Science Leader magazine, discusses the many changes that have occurred in his job and the jobs of some of our pharma subscribers due to the COVID-19 pandemic. He also discusses one reader's unique idea regarding some inspiring stories that have cropped up during this current crisis. 

What has the coronavirus outbreak taught us about the pharmaceutical supply chain? A lot, and some of it's not good, according to our guest today, Louis Garguilo, Chief Editor of Outsourced Pharma.

Bioprocess Online Chief Editor Matt Pillar gives some background on his provocative new article, “Is Biopharma's Response To Coronavirus Off The Mark?” He also discusses his feature story, “The Perilous Development of a Potential Biologic Blockbuster,” and why it's one of the most read articles on his site. (For additional information on Life Science Connect and its network of online resources, visit Life Science Connect). 

Cell & Gene Chief Editor Erin Harris is the guest on the podcast today. She discusses some of the top names on her editorial advisory board and gives a glimpse into the 2020 outlook articles that the board has been authoring. 

Life Science Leader Chief Editor Rob Wright gives a behind-the-scenes look at his upcoming feature articles on Blueprint Medicines and Arrowhead Pharmaceuticals as well as an intriguing question submitted to his editorial board.

On today's episode of the Life Science Connect podcast, Clinical Leader Chief Editor Ed Miseta talks about a virtual conference on patient centricity called “Focus On Patients,” covering the successes and challenges of putting patients at the center of clinical trials.

In this episode, Life Science Leader magazine Chief Editor Rob Wright talks about what he learned while attending this year's JPM Conference and some of the other peripheral life sciences events that go on in San Francisco during early January. He discusses some sessions he sat in, after-hours events he attended, and a few of the many executives he spoke with, some of whom will appear in future issues of the magazine.